Bayesian evaluation of a physiologically-based pharmacokinetic (PBPK) model of long-term kinetics of metal nanoparticles in rats

被引:35
|
作者
Sweeney, Lisa M. [1 ,2 ]
MacCalman, Laura [3 ]
Haber, Lynne T. [2 ]
Kuempel, Eileen D. [4 ]
Lang Tran, C. [3 ]
机构
[1] Henry M Jackson Fdn Adv Mil Med, Naval Med Res Unit Dayton NAMRU Dayton, Wright Patterson AFB, OH 45433 USA
[2] Toxicol Excellence Risk Assessment, Cincinnati, OH 45211 USA
[3] Inst Occupat Med, Edinburgh EH14 4AP, Midlothian, Scotland
[4] NIOSH, Cincinnati, OH 45226 USA
关键词
Nanoparticles; Physiologically-based pharmacokinetic model; Bayesian analysis; Markov chain Monte Carlo; INSOLUBLE IRIDIUM PARTICLES; TISSUE DISTRIBUTION; SILVER NANOPARTICLES; TOXICODYNAMIC MODELS; RISK-ASSESSMENT; TRANSLOCATION; CLEARANCE; LUNG; TRICHLOROETHYLENE; BIODISTRIBUTION;
D O I
10.1016/j.yrtph.2015.06.019
中图分类号
DF [法律]; D9 [法律]; R [医药、卫生];
学科分类号
0301 ; 10 ;
摘要
Biomathematical modeling quantitatively describes the disposition of metal nanoparticles in lungs and other organs of rats. In a preliminary model, adjustable parameters were calibrated to each of three data sets using a deterministic approach, with optimal values varying among the different data sets. In the current effort, Bayesian population analysis using Markov chain Monte Carlo (MCMC) simulation was used to recalibrate the model while improving assessments of parameter variability and uncertainty. The previously-developed model structure and some physiological parameter values were modified to improve physiological realism. The data from one of the three previously-identified studies and from two other studies were used for model calibration. The data from the one study that adequately characterized mass balance were used to generate parameter distributions. When data from a second study of the same nanomaterial (iridium) were added, the level of agreement was still acceptable. Addition of another data set (for silver nanoparticles) led to substantially lower precision in parameter estimates and large discrepancies between the model predictions and experimental data for silver nanoparticles. Additional toxicokinetic data are needed to further evaluate the model structure and performance and to reduce uncertainty in the kinetic processes governing in vivo disposition of metal nanoparticles. (C) 2015 Elsevier Inc. All rights reserved.
引用
收藏
页码:151 / 163
页数:13
相关论文
共 50 条
  • [1] A physiologically-based pharmacokinetic (PBPK) model of hydroxychloroquine
    Collins, Keagan P.
    Jackson, Kristen M.
    Gustafson, Daniel L.
    [J]. CANCER RESEARCH, 2017, 77
  • [2] Physiologically-based pharmacokinetic (PBPK) model to describe the disposition of pyronaridine
    Diep, John K.
    Lingerfelt, Mary A.
    Ekins, Sean
    Rao, Gauri G.
    [J]. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2017, 44 : S34 - S34
  • [3] PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODEL FOR PANTOPRAZOLE IN CHILDREN WITH OBESITY
    Kyler, K.
    Shakhnovich, V.
    Selvarangan, R.
    Sasidharan, A.
    Chan, S.
    Artz, N.
    Williams, V.
    Friesen, C.
    Pearce, R.
    Gaedigk, A.
    Leeder, J.
    Galetin, A.
    Johnson, T.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S106 - S107
  • [4] A physiologically-based pharmacokinetic/pharmacodynamic (PBPK/PD) model for the insecticide dimethoate
    Reiss, Richard
    Loccisano, Anne
    Deines, Andrew
    Kim, Myoungwoo
    Nallani, Gopinath
    Chandrasekaran, Appavu
    Whatling, Paul
    [J]. XENOBIOTICA, 2023, 53 (05) : 382 - 395
  • [5] PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELING OF MEROPENEM IN PRETERM AND TERM INFANTS.
    Ganguly, S.
    Edginton, A.
    Gerhart, J.
    Cohen-Wolkowiez, M.
    Greenberg, R.
    Gonzalez, D.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S11 - S12
  • [6] A physiologically-based pharmacokinetic model of drug detoxification by nanoparticles
    Fallon, MS
    Varshney, M
    Dennis, DM
    Chauhan, A
    [J]. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2004, 31 (05) : 381 - 400
  • [7] A Physiologically-Based Pharmacokinetic Model of Drug Detoxification by Nanoparticles
    Marissa S. Fallon
    Manoj Varshney
    Donn M. Dennis
    Anuj Chauhan
    [J]. Journal of Pharmacokinetics and Pharmacodynamics, 2004, 31 : 381 - 400
  • [8] A physiologically-based pharmacokinetic (PBPK) model for alcohol facilitates rapid BrAC clamping
    Ramchandani, VA
    Bolane, J
    Li, TK
    O'Connor, S
    [J]. ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 1999, 23 (04) : 617 - 623
  • [9] Bayesian Population Physiologically-Based Pharmacokinetic (PBPK) Approach for a Physiologically Realistic Characterization of Interindividual Variability in Clinically Relevant Populations
    Krauss, Markus
    Tappe, Kai
    Schuppert, Andreas
    Kuepfer, Lars
    Goerlitz, Linus
    [J]. PLOS ONE, 2015, 10 (10):
  • [10] Physiologically-based Pharmacokinetic (PBPK) Models for Assessing the Kinetics of Xenobiotics during Pregnancy: Achievements and Shortcomings
    Lu, G.
    Abduljalil, K.
    Jamei, M.
    Johnson, T. N.
    Soltani, H.
    Rostami-Hodjegan, A.
    [J]. CURRENT DRUG METABOLISM, 2012, 13 (06) : 695 - 720